Portopulmonary hypertension

Journal of Clinical Gastroenterology

Volumn 45, Issue 8, 2011, Pages 703-710

  Mukhtar, Nizar A ^a   Fix, Oren K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cirrhosis; end stage liver disease; liver transplantation; portopulmonary hypertension; pulmonary hypertension

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; TADALAFIL; UNIPROST; VASODILATOR AGENT;

ANTICOAGULANT THERAPY; ARTERIAL GAS; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD GAS ANALYSIS; CATHETER INFECTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; COUGHING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DIURETIC THERAPY; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; END STAGE LIVER DISEASE; EPIDEMIOLOGICAL DATA; ESOPHAGUS VARICES BLEEDING; GASTROESOPHAGEAL VARICES; GASTROINTESTINAL HEMORRHAGE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPOXEMIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG HEMODYNAMICS; NAUSEA; PATHOPHYSIOLOGY; PATIENT SAFETY; PHYSICAL EXAMINATION; PORTOPULMONARY HYPERTENSION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY ALKALOSIS; REVIEW; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SPLENOMEGALY; SURGICAL RISK; SURVIVAL RATE; SYMPTOM; SYSTOLIC BLOOD PRESSURE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION; VEIN THROMBOSIS; VOMITING;

ANTIHYPERTENSIVE AGENTS; HEMODYNAMICS; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER DISEASES; LIVER TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 80052032134     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31820656bd     Document Type: Review

References (52)

1. Rodriguez-Roisin R, Krowka MJ, Herve P, et al. Pulmonary- Hepatic vascular Disorders (PHD). Eur Respir J. 2004;24: 861-880. (Pubitemid 39504442)
2. Mantz FA Jr, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol. 1951;52:91-97.
3. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6: 443-450. (Pubitemid 30489117)
4. Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. (Pubitemid 40770295)
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S43-S54.
6. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med. 2008;75:121-122. 125-130.
7. Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology. 2006;44:1502-1510. (Pubitemid 44953655)
8. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178:637-643.
9. Iqbal CW, Krowka MJ, Pham TH, et al. Liver transplantation for pulmonary vascular complications of pediatric end-stage liver disease. J Pediatr Surg. 2008;43:1813-1820.
10. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis. 1983;127:437-441. (Pubitemid 13083742)
11. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401-409. (Pubitemid 36152540)
12. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J. 1998;11: 1153-1166. (Pubitemid 28281039)
13. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48:196-203. (Pubitemid 351975544)
14. Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: mayo clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8:2445-2453.
15. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655-1665.
16. Neuhofer W, Gulberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest. 2006;36(suppl 3):54-61. (Pubitemid 44179783)
17. Pellicelli AM, Barbaro G, Puoti C, et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology. 2010; 61:802-806.
18. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99:249-254.
19. Lederer DJ, Horn EM, Rosenzweig EB, et al. Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulm Pharmacol Ther. 2008;21:112-114.
20. Roberts KE, Fallon MB, Krowka MJ, et al. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest. 2009;135:1470-1475.
21. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835-842.
22. Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl. 2000;6:85-91. (Pubitemid 30123373)
23. Yang YY, Lin HC, Lee WC, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol. 2001;36:181-186.
24. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352:719-725. (Pubitemid 28398718)
25. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6:453-458. (Pubitemid 30489119)
26. Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation. 2001;71:572-574. (Pubitemid 32207211)
27. Hua R, Sun YW,Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. Hepatobiliary Pancreat Dis Int. 2009;8:157-161.
28. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10:174-182. (Pubitemid 38240114)
29. Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl. 2005;11:1107-1111. (Pubitemid 41341761)
30. Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. Chest. 1997;112:980-986. (Pubitemid 27446318)
31. Kim YK, Kim Y, Shim SS. Thoracic complications of liver cirrhosis: radiologic findings. Radiographics. 2009;29:825-837.
32. Swanson KL, Krowka MJ. Arterial oxygenation associated with portopulmonary hypertension. Chest. 2002;121:1869-1875. (Pubitemid 34634408)
33. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129:1313-1321.
34. Bernal V, Pascual I, Esquivias P, et al. N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension. Transplant Proc. 2009;41: 987-988.
35. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidencebased treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S78-S84.
36. Provencher S, Herve P, Jais X, et al. Deleterious effects of betablockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006; 130:120-126. (Pubitemid 43049842)
37. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296-302.
38. Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl. 2007;13:875-885. (Pubitemid 46939441)
39. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation. 1997;63:604-606. (Pubitemid 27102632)
40. Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641-648. (Pubitemid 29409407)
41. Ashfaq M, Chinnakotla S, Rogers L, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant. 2007;7:1258-1264. (Pubitemid 46643089)
42. Melgosa MT, Ricci GL, Garcia-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl. 2010;16:348-356.
43. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30:1096-1102. (Pubitemid 351194755)
44. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293-299. (Pubitemid 36135255)
45. Sakai T, Planinsic RM, Mathier MA, et al. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Transpl Int. 2009;22:554-561.
46. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology. 2005;128:164-168. (Pubitemid 40039967)
47. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25:502-508. (Pubitemid 40331181)
48. Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest. 2010. [Epub ahead of print].
49. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971-1981.
50. Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28:563-567. (Pubitemid 44794671)
51. Rafanan AL, Maurer J, Mehta AC, et al. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. Chest. 2000;118:1497-1500.
52. Koneru B, Fisher A, Wilson DJ, et al. De novo diagnosis of portopulmonary hypertension following liver transplantation. Am J Transplant. 2002;2:883-886. (Pubitemid 36306846)